Evaluation of neuroprotective qualities of brimonidine during LASIK

被引:19
|
作者
McCarty, TM
Hardten, DR
Anderson, NJ
Rosheim, K
Samuelson, TW
机构
[1] Minnesota Eye Consultants, Minneapolis, MN 55404 USA
[2] Reg Med Ctr, St Paul, MN USA
[3] Univ Minnesota, Minneapolis, MN 55455 USA
关键词
D O I
10.1016/S0161-6420(03)00476-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The effects of LASIK-induced increased intraocular pressure on the optic nerve and nerve fiber layer are poorly understood. This study evaluates the effect of LASIK on several optic nerve parameters, both structural (scanning laser polarimetry) and functional (automated perimetry). In addition, the potential neuroprotective effect of perioperative brimonidine is studied. Design: Randomized self-control led, masked trial. Participants: Fifty-one patients scheduled for routine, bilateral, myopic LASIK. Patients served as their own control and received brimonidine in one eye and placebo in their fellow eye. Methods: Patients were treated with the VISX Star S3 Excimer Laser. Patients were evaluated preoperatively and at 1 day, 1 month, and 3 months after LASIK Topical brimonidine or control vehicle was administrated three times daily for 3 days before surgery. In addition, 1 drop of the respective study drug was instilled at the end of the procedure, and the patient continued the study drug three times daily for 3 weeks after surgery in the respective (randomized) eye. Main Outcome Measures: Visual acuity, nerve fiber layer analysis, automated visual field, contrast sensitivity, color vision, and pupillary function. Results: Brimonidine did not change the outcome of any of the parameters analyzed in this study. There was not a statistically significant change in any of the visual field parameters (mean elevation or depression, pattern standard deviation, and corrected pattern standard deviation) measured in either the placebo or brimonidine group postoperatively. However, both the placebo and brimonidine group did show a statistically significant change in many of the direct Nerve Fiber Analyzer GDx (NFA GDx) measures. The average thickness, ellipse, and superior average were generally reduced in both groups. There was, however, no statistically significant change after LASIK in either group in indirect NFA GDx parameters such as symmetry, superior ratio, inferior ratio, or superior/nasal ratio. There was no significant change in optic nerve appearance, contrast sensitivity, or color vision between treatment groups before or after LASIK. Conclusions: LASIK with or without brimonidine did not affect the structure or function of the parameters of the optic nerve studied. Direct NFA GDx measures were globally reduced after myopic LASIK; however, the ratio measures were generally unaffected. The reduction in direct, retinal nerve fiber layer measures, in the absence of change in ratio measures and other optic nerve parameters and absence of brimonidine effect, suggest an alteration in corneal birefringence after excimer laser ablation. (C) 2003 by the American Academy of Ophthalmology.
引用
收藏
页码:1615 / 1625
页数:11
相关论文
共 50 条
  • [1] Prophylactic brimonidine before LASIK
    Üretmen, N
    Ates, H
    Andaç, K
    JOURNAL OF REFRACTIVE SURGERY, 2003, 19 (05) : 612 - 612
  • [2] Neuroprotective effect of brimonidine
    Lai, RK
    Hasson, DW
    Wheeler, LA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 2750 - 2750
  • [3] Neuroprotective agent brimonidine: A toxicity study
    Kalapesi, FB
    Hill, MA
    Coroneo, MT
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U740 - U740
  • [4] Evidence on the neuroprotective properties of brimonidine in glaucoma
    Scuteri, Damiana
    Bagetta, Giacinto
    Nucci, Carlo
    Aiello, Francesco
    Cesareo, Massimo
    Tonin, Paolo
    Corasaniti, Maria Tiziana
    GLAUCOMA: A NEURODEGENERATIVE DISEASE OF THE RETINA AND BEYOND - PT B, 2020, 257 : 155 - 166
  • [5] Neuroprotective effect of ocular hypotensive agent brimonidine
    Lai, R
    Hasson, D
    Chun, T
    Wheeler, L
    SOE '97 - XI CONGRESS OF THE EUROPEAN SOCIETY OF OPHTHALMOLOGY, VOLS 1 AND 2, 1997, : 439 - 444
  • [6] Neuroprotective effect of brimonidine in chronic ocular hypertensive rats
    WoldeMussie, E
    Ruiz, G
    Wijono, M
    Wheeler, LA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S830 - S830
  • [7] Dilute Brimonidine to Improve Patient Comfort and Subconjunctival Hemorrhage After LASIK
    Pasquali, Theodore A.
    Aufderheide, Adam
    Brinton, Jason P.
    Avila, Michele R.
    Stahl, Erin D.
    Durrie, Daniel S.
    JOURNAL OF REFRACTIVE SURGERY, 2013, 29 (07) : 469 - 475
  • [8] Preclinical evaluation of brimonidine
    Burke, J
    Schwartz, M
    SURVEY OF OPHTHALMOLOGY, 1996, 41 : S9 - S18
  • [9] Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
    Conti, Federica
    Romano, Giovanni Luca
    Eandi, Chiara Maria
    Toro, Mario Damiano
    Rejdak, Robert
    Di Benedetto, Giulia
    Lazzara, Francesca
    Bernardini, Renato
    Drago, Filippo
    Cantarella, Giuseppina
    Bucolo, Claudio
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Exploring Neuroprotective Effects of Topical Brimonidine in Experimental Diabetic Retinopathy
    Jung, Kyoung in
    Kim, Jie hyun
    Han, Jeong-sun
    Park, Chan kee
    IN VIVO, 2024, 38 (04): : 1609 - 1620